Poster Presentations(P)

  1. Special Lecture(SL)
  2. CNP Paul Janssen Awards(PJ)
  3. Prize for Encouragement of the society(EN)
  4. Luncheon Seminar(LS)
  5. Poster Presentations(P)

P1A-4

Electroconvulsive shock affected microglial activation in the hippocampus of Gunn rat and ameliorated their schizophrenia-like behavior

Erlyn Limoa1、Sadayuki Hashioka2、Tsuyoshi Miyaoka2、Keiko Tsuchie2、 Ryosuke Arauchi2、Ilhamuddin Abdul Azis1,2、Rei Wake2,3、Maiko Hayashida2、Tomoko Araki2、Tomohide Furuya2,4、Kristian Liaury1、 Andi Jayalangkara Tanra1、Jun Horiguchi2

  1. Department of Psychiatry, Hasanuddin University. Makassar, Indonesia
  2. Department of Psychiatry, Faculty of Medicine, Shimane University
  3. Faculty of Human Sciences, Shimane University
  4. Department of Developmental Biology, Shimane University

Electroconvulsive shock (ECS) is regarded as one of the efficient treatments for intractable psychiatric disorders, but the mechanism remains unclear. Recently, many studies indicate that ECS affects the immune system, including microglia. We previously demonstrated that Gunn rats showed schizophrenia-like behavior and microglial activation in their brains. In this study we examined the effects of ECS on schizophrenia-like behavior and microgliosis in the hippocampus of Gunn rats. We found prepulse inhibition (PPI) deficit in Gunn rats was significantly improved by ECS. The expression of CD11b was significantly higher in the Gunn rats and ECS attenuated this expression. The effect of ECS on PPI test started to decrease from 1 week after the last administration of ECS. The long-lasting effect of ECS on microglial activation in the hippocampus will be shown in the poster presentation.We concluded that ECS ameliorates schizophrenia-like behavior in Gunn rats and attenuates microglial activation in the hippocampus of Gunn rats. Accordingly, therapeutic effects of ECS may be exerted, at least in part, by inhibition of glial activation. Effect of ECS on schizophrenia-like behavior in Gunn rat started to reduce in 1 week after the last ECS. This finding suggests that continuous or maintenance ECS treatments may be effective as a relapse prevention treatment.




P1C-3

SALIVARY ALPHA-AMYLASE (sAA) AS A BIOMARKER FOR THE RESPONSE OF THERAPY IN SCHIZOPHRENIA PATIENTS

Erlyn Limoa1,2、Tsuyoshi Miyaoka2、Kristian Liaury1、Sonny Lisal1、Jun Horiguchi2、Andi Jayalangkara Tanra1

  1. Department of Psychiatry, Hasanuddin University. Makassar, Indonesia
  2. Department of Psychiatry, Faculty of Medicine, Shimane University

Reliable biology indicators for stress reaction and psychopathology are valuable markers for both psychological research and clinical practice. Recently, the measurement of salivary alpha-amylase (sAA) was introduced as a non-invasive and more convenience protocol. Several studies showed the high sensitivity of sAA level in various mental disorders, unfortunately there still no data on how the level of sAA in naive-drugs of schizophrenia patients. In this study we want to determine whether sAA level could be as potential biomarker for therapeutic response in schizophrenia patients. By using the cohort study, we collected 30 samples that met the inclusion criteria and 30 normal control samples. sAA level and PANSS score were taken 5 times at baseline, 3 days after treatment of antipsychotics, 5 days after treatment, 7 days, and 14 days after treatment of antipsychotics. We found that schizophrenia patients showed significant higher sAA levels compared to normal control group. sAA levels showed significant decline in correlation with the improvement of PANSS score within 2 weeks of antipsychotics therapy. This finding suggested that the measurement of sAA levels can be used as potential biomarker of therapeutic response in schizophrenia patients.This research has been approved by the ethics committee of Hasanuddin University, we provided informed consent for all participants and we keep confidentiality and provide anonymity by all means.




P1H-5

Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-analysis of Double-blind, Randomized, Controlled Trials

Hiroyoshi Takeuchi1,2、Ali Fathi2、Sadhana Thiyanavadivel2、Ofer Agid2、Gary Remington2

  1. Department of Neuropsychiatry, School of Medicine, Keio University
  2. Schizophrenia Division, Complex Care & Recovery Program, Centre for Addiction and Mental Health, Toronto, Canada

【Background】There have been numerous case reports reporting psychotic worsening when switching to or adding aripiprazole in patients with schizophrenia. We evaluated the risk of psychotic worsening related to aripiprazole.
【Methods】MEDLINE, Embase, and CENTRAL were systematically searched. Double-blind, randomized, controlled trials involving a switch to, or addition of, aripiprazole in schizophrenia spectrum disorders were selected. Number of patients who experienced psychotic worsening, agitation, or anxiety as well as those who discontinued the study due to all causes, lack of efficacy, or adverse events were extracted.
【Results】A total of 22 studies (13 switching and 9 adding studies) involving 5,769 patients that met eligibility criteria were included in the meta-analysis. Psychotic worsening was reported as an adverse event in all studies. No significant difference in the risk of psychotic worsening was found between switching to aripiprazole and switching to other antipsychotics (RR=1.17, 95% CI=0.97-1.42, P=0.10); however, switching to aripiprazole was related to a significantly greater risk of study discontinuation due to lack of efficacy (RR=1.46, 95% CI=1.10- 1.93, P=0.009). Lack of data resulted in no conclusive results as to clinical risks of adding aripiprazole.
【Conclusions】Findings suggest that there is no direct evidence that a switch to aripiprazole is related to risk of psychotic worsening in participants in clinical trials, although a switch to aripiprazole may be associated with a higher risk of study discontinuation due to lack of efficacy.

Page Top

  1. Special Lecture(SL)
  2. CNP Paul Janssen Awards(PJ)
  3. Prize for Encouragement of the society(EN)
  4. Luncheon Seminar(LS)
  5. Poster Presentations(P)